In this regard, miR-206 inhibits hepatosteatosis and hyperglycemia in MASLD by regulating phosphatase non-receptor type 1 (PTPN1), as well as its downstream sterol regulatory element-binding protein 1c (SREBP1C) signaling pathway [48]; in addition, miR-372-3p decreases AE binding protein 1 expression levels, a central regulator driving fibrosis in MASLD [49]. Here, PTPN1 is linked to metabolic dysfunction-associated steatotic liver disease.